📊 CRVO Key Takeaways
Is CervoMed Inc. (CRVO) a Good Investment?
CervoMed has zero revenue, operating losses of $8.1M, and negative free cash flow of $8.5M, burning through its $7.9M cash position at an unsustainable rate. The company faces critical solvency risk within quarters without revenue generation or capital injection, despite its favorable capital structure with no debt.
CervoMed's fundamentals are extremely weak, with revenue down 58.9% year over year, zero gross profit, and deeply negative operating and net margins that indicate the current business model is not generating sustainable economics. While the balance sheet is relatively clean with no long-term debt and a solid current ratio, the company's cash burn is severe versus its cash balance, creating meaningful funding risk unless operating performance improves materially.
CervoMed Inc. Key Strengths (CRVO)
- Strong liquidity position with 3.25x current ratio and quick ratio
- No long-term debt, providing flexibility and reducing financial risk
- Substantial cash balance of $7.9M relative to total liabilities of $4.5M
- Debt-free balance sheet with no long-term debt reduces financial leverage risk
- Current and quick ratios of 4.91x indicate near-term liabilities are currently manageable
- Positive reported revenue base, however small, provides some operating activity rather than being entirely pre-revenue
CRVO Stock Risks: CervoMed Inc. Investment Risks
- Zero revenue with no visible path to commercialization in near term
- Severe cash burn rate of $8.0-8.5M per period threatening solvency within 1 period
- Negative profitability metrics (ROE -75%, ROA -52.7%) indicating fundamental operational failure
- No insider transactions in 90 days suggests management lacks confidence in company viability
- Pre-revenue or failed-stage pharma company with no demonstrated product-market fit
- Revenue contraction of 58.9% year over year signals weak growth quality and poor commercial traction
- Operating loss of $28.29M and free cash flow of -$23.90M show unsustainably high cash burn
- ROE of -148.0% and ROA of -117.9% reflect severe value destruction and inefficient asset use
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue generation or clinical trial progress milestones
- Capital raise announcements, partnerships, or acquisition interest
- Quarterly operating cash burn relative to cash and equivalents
- Revenue stabilization and improvement in operating margin
CervoMed Inc. (CRVO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.25x current ratio provides a solid financial cushion.
CRVO Profit Margin, ROE & Profitability Analysis
CRVO vs Healthcare Sector: How CervoMed Inc. Compares
How CervoMed Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CervoMed Inc. Stock Overvalued? CRVO Valuation Analysis 2026
Based on fundamental analysis, CervoMed Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CervoMed Inc. Balance Sheet: CRVO Debt, Cash & Liquidity
CRVO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CervoMed Inc.'s revenue has grown significantly by 36% over the 5-year period, indicating strong business expansion. The most recent EPS of $1,946,859.00 reflects profitable operations.
CRVO Revenue Growth, EPS Growth & YoY Performance
CRVO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$4.9M | N/A |
| Q3 2025 | $322.6K | -$4.8M | N/A |
| Q2 2025 | $1.8M | -$2.3M | N/A |
| Q1 2025 | $1.9M | -$2.5M | N/A |
| Q3 2024 | $1.5M | $190.5K | $-0.55 |
| Q2 2024 | $1.7M | -$1.4M | N/A |
| Q1 2024 | $1.4M | -$534.3K | N/A |
| Q3 2023 | N/A | $190.5K | $-0.70 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CervoMed Inc. Dividends, Buybacks & Capital Allocation
CRVO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CervoMed Inc. (CIK: 0001053691)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRVO
What is the AI rating for CRVO?
CervoMed Inc. (CRVO) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRVO's key strengths?
Claude: Strong liquidity position with 3.25x current ratio and quick ratio. No long-term debt, providing flexibility and reducing financial risk. ChatGPT: Debt-free balance sheet with no long-term debt reduces financial leverage risk. Current and quick ratios of 4.91x indicate near-term liabilities are currently manageable.
What are the risks of investing in CRVO?
Claude: Zero revenue with no visible path to commercialization in near term. Severe cash burn rate of $8.0-8.5M per period threatening solvency within 1 period. ChatGPT: Revenue contraction of 58.9% year over year signals weak growth quality and poor commercial traction. Operating loss of $28.29M and free cash flow of -$23.90M show unsustainably high cash burn.
What is CRVO's revenue and growth?
CervoMed Inc. reported revenue of $0.0.
Does CRVO pay dividends?
CervoMed Inc. does not currently pay dividends.
Where can I find CRVO SEC filings?
Official SEC filings for CervoMed Inc. (CIK: 0001053691) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRVO's EPS?
CervoMed Inc. has a diluted EPS of $-1.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CRVO's fundamental grade?
Based on our AI fundamental analysis in June 2026, CervoMed Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CRVO stock overvalued or undervalued?
Valuation metrics for CRVO: ROE of -75.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CRVO's AI grade for 2026?
Our dual AI analysis gives CervoMed Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRVO's free cash flow?
CervoMed Inc.'s operating cash flow is $-8.0M, with capital expenditures of $447.8K.
How does CRVO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -75.0% (avg: 15%), current ratio 3.25 (avg: 2).